Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 7Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Healthy Volunteer 1Healthy Adults 1Glioblastoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Peptides × Clear all
NCT03223103 2025-09-10

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Albert Einstein College of Medicine

Phase 1 Active not recruiting
13 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡